Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesobotox split-body trial for hidradenitis suppurativa
IRCT20241115063720N2Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of neuronox in hidradenitis suppurativa (HS) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Clinical response based on inflammatory lesion count. Started Sep 2026; status: completed.
02
Drugs
neuronox
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on IRCT20241115063720N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241115063720N2.